芳香酶抑制剂（AI）是一类用于辅助治疗乳腺癌的药物。最近的病例报告表明，AI 可能与各种眼部不良事件 (AE) 相关。本研究评估服用 AI 的患者发生眼部 AE 的风险。使用美国食品和药物管理局不良事件报告系统数据库 2004 年至 2022 年的数据进行不成比例分析。所有玻璃体黄斑牵引、黄斑水肿、视网膜沉积、视网膜沉积的病例检索了动脉闭塞、黄斑裂孔、视网膜出血、葡萄膜炎、视网膜撕裂、视网膜脱离、干眼病、睑缘炎和视神经病变的 3 个 AI，包括阿那曲唑、来曲唑和依西美坦。还对曲妥珠单抗作为对照进行了搜索。计算了报告的比值比 (ROR) 和相应的 95% CI。我们确定了 3 种 AI 的 322 种感兴趣的眼部 AE，曲妥珠单抗的 55 种。阿那曲唑的 AE 最多 (n=163)，并且被发现与玻璃体黄斑牵引 (ROR=665；95% CI，352-1255)、黄斑水肿 (ROR=37；95% CI，25-54)、视网膜沉积物（ROR=11；95% CI，2-77）和葡萄膜炎（ROR=6；95% CI，4-9）。来曲唑与视网膜沉积物（ROR=8，95% CI，1-57）和视网膜动脉闭塞（ROR=6；95% CI，3-11）有很强的相关性。依西美坦与黄斑裂孔有很强的相关性（ROR=10；95% CI，3-30）。不成比例分析显示，每种 AI 导致眼部 AE 的风险增加。这项研究呼吁临床医生，尤其是肿瘤科医生和眼科医生，对接受 AI 治疗的患者保持警惕，以便他们能够及时提供干预措施，以减轻进一步的眼部发病率。版权所有 © 2023。由 Elsevier Inc. 出版。

Aromatase inhibitors (AIs) are a class of medications used for adjuvant treatment of breast cancer. Recent case reports suggest that AIs may be associated with various ocular adverse events (AEs). This study evaluates the risk of ocular AEs in patients who take AIs.Disproportionality analysis was performed using data from the U.S. Food and Drug Administration's Adverse Events Reporting System database from 2004 to 2022. All cases of vitreomacular traction, macular edema, retinal deposits, retinal artery occlusion, macular hole, retinal hemorrhage, uveitis, retinal tear, retinal detachment, dry eye disease, blepharitis, and optic neuropathy were searched for the 3 AIs anastrozole, letrozole, and exemestane. A search also was performed on trastuzumab as a control. Reported odds ratios (RORs) and corresponding 95% CIs were computed.We identified 322 ocular AEs of interest for the 3 AIs and 55 for trastuzumab. Anastrozole had the most AEs (n = 163) and was found to have strong associations with vitreomacular traction (ROR = 665; 95% CI, 352-1255), macular edema (ROR = 37; 95% CI, 25-54), retinal deposits (ROR = 11; 95% CI, 2-77), and uveitis (ROR = 6; 95% CI, 4-9). Letrozole had strong associations with retinal deposits (ROR = 8, 95% CI, 1-57) and retinal artery occlusion (ROR = 6; 95% CI, 3-11). Exemestane had a strong association with macular holes (ROR = 10; 95% CI, 3-30).Disproportionality analysis revealed an increased risk of ocular AEs with each of the AIs. This study calls for clinicians, especially oncologists and ophthalmologists, to be vigilant in patients who are on AI therapy, allowing them to provide prompt interventions to mitigate further ocular morbidities.Copyright © 2023. Published by Elsevier Inc.